Today’s agenda

15:00 CET  IAS – Welcome and introduction
5 minutes  Sébastien Morin (IAS)

15:05 CET  WHO – Guidelines uptake and PADO priorities
15 minutes Martina Penazzato (WHO)

15:20 CET  PHTI – Update on PHTI projects
10 minutes Fernando Pascual (MPP)

15:30 CET  IATT – Update on IATT formulary + uptake
10 minutes Nandita Sugandhi (CHAI)

15:40 CET  PAPWG – Update on PAPWG + expansion to adult ARVs
10 minutes Wesley Kreft (PFSCM)

15:50 CET  CTA – Updates on fast-tracking development and introduction of paediatric formulations
10 minutes George Siberry (PEPFAR)

16:00 CET  Q&A (from the chat)
25 minutes All participants (moderated by Sébastien Morin, IAS)

16:25 CET  IAS – Closing remarks
5 minutes  Sébastien Morin (IAS)
CTA Meeting on Paediatric ARVs:

Introducing the Global Accelerator for Paediatric Formulations (GAPf)

Mövenpick Hotel, Geneva (Switzerland)

Monday, 5 December 2016, 17:00 – 21:00
The GAPf builds on existing initiatives
Proposed staged approach: GAPf development and implementation

1. Activities that require little or no additional funding, but advance the Global Accelerator agenda.

2. Global Accelerator hosted by UNITAID as an evolution of PHTI in its scope, mission and operationalization.

3. Full development of the Global Accelerator with broad focus on paediatric formulation to be included in existing PPP or to into and independent entity. (Pending successful completion of stage 1 and 2)
Next steps (early 2017 and beyond)

• Refine the proposed action plan based on the feedback received
• Broadly disseminate the revised concept and action plan
• Continue and expand Stage 1 activities
• Launch Stage 2 activities in parallel
• Prepare the ground for Stage 3
• Track progress through CTA partnership
Thanks to CTA partners and their sponsors

ILF Corporate Partners 2016

GOLD PARTNERS

GILEAD  
MSD  
ViiV Healthcare

SILVER PARTNERS

The Global Fund  
abbvie  
Alere  
Janssen

BRONZE PARTNERS

World Health Organization  
UNITAID

CIPHER FOUNDING SPONSOR

Abbott  
bioLytical  
Cepheid

ViiV Healthcare  
Cipla  
Roche  
sysmex

Janssen  
FHC  
Omega Diagnostics